

Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K

NEKTAR THERAPEUTICS

Form 8-K

February 02, 2004

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2004

NEKTAR THERAPEUTICS  
(Exact name of Registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

0-23556  
(Commission  
File Number)

94-3134940  
(IRS Employer  
Identification No.)

150 Industrial Road  
San Carlos, California 94070  
(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (650) 631-3100

---

Item 12. Results of Operations and Financial Condition

On February 2, 2004, Nektar Therapeutics issued a press release announcing results for the quarter and the year ended December 31, 2003. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is

## Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K

incorporated herein by reference.

The information in this report, including the exhibit hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

### SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

By: /s/ AJIT S. GILL  
-----  
Ajit S. Gill  
Chief Executive Officer,  
President and Director

Date: February 2, 2004

By: /s/ AJAY BANSAL  
-----  
Ajay Bansal  
Chief Financial Officer and Vice  
President, Finance and  
Administration

Date: February 2, 2004

### EXHIBIT INDEX

Exhibit No.	Description
-----	-----
99.1	Earnings Press Release of Nektar Therapeutics dated February 2, 2004.

left-width: 1; border-right-width: 1; border-bottom-width: 1">1.Title of Security  
(Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code  
(Instr. 8)4. Securities Acquired (A) or Disposed of (D)

# Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K

(Instr. 3, 4 and 5)5. Amount of Securities Beneficially Owned Following Reported Transaction(s)

(Instr. 3 and 4)6. Ownership Form: Direct (D) or Indirect (I)

(Instr. 4)7. Nature of Indirect Beneficial Ownership

(Instr. 4)CodeVAmount(A) or (D)Price Common Stock11/15/2010 P 300 A \$ 5.34 1,462,014 D Common Stock11/15/2010 P 2,200 A \$ 5.35 1,464,214 D Common Stock11/15/2010 P 500 A \$ 5.4 1,464,714 D Common Stock11/15/2010 P 100 A \$ 5.47 1,464,814 D Common Stock11/15/2010 P 902 A \$ 5.5 1,465,716 D Common Stock11/15/2010 P 200 A \$ 5.3 1,465,916 D Common Stock11/15/2010 P 1,800 A \$ 5.55 1,467,716 D Common Stock11/16/2010 P 500 A \$ 5.26 1,468,216 D Common Stock11/16/2010 P 200 A \$ 5.29 1,468,416 D Common Stock11/16/2010 P 4,684 A \$ 5.3 1,473,100 D Common Stock11/16/2010 P 500 A \$ 5.37 1,473,600 D Common Stock11/16/2010 P 500 A \$ 5.38 1,474,100 D Common Stock11/16/2010 P 500 A \$ 5.39 1,474,600 D Common Stock 173,333 I Icarus Investment Corp. (Ontario) <sup>(1)</sup> Common Stock 1,334,360 I Icarus Investment Corp. (Delaware) <sup>(2)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.** SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
DEZWIREK PHILLIP 2300 YONGE STREET, SUITE 1710 PO BOX 2408 TORONTO, A6 M4P 1E4	X	X	Chairman	

## Signatures

/s/ Kathryn A. Erickson as Attorney-in-Fact for Phillip  
DeZwirek

11/17/2010

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Filer is a director and 1% owner.

(2) Owned 50% by filer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.